Protective effect of urate oxidase on uric acid induced-monocyte apoptosis

Current Drug Discovery Technologies

Volumn 2, Issue 1, 2005, Pages 29-36

  Bordoni, Valeria ^a   De Cal, Massimo ^a   Rassu, Mario ^a   Cazzavillan, Stefania ^a   Segala, Chiara ^a   Bonello, Monica ^a   Ranishta, Rattanarat ^a   Andrikos, Emilios ^a   Yavuz, Asuman ^a   Salvatori, Gabriella ^a   Galloni, Elisabetta ^a   Bolgan, Irene ^a   Bellomo, Rinaldo ^b   Levin, Nathan ^c   Ronco, Claudio ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b AUSTIN HOSPITAL   (Australia)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Inflammation; Monocytes; Renal insufficiency; Urate oxidase; Uric acid

Indexed keywords

ALLANTOIN; CASPASE 3; CASPASE 8; GLUTATHIONE; RASBURICASE; URATE OXIDASE; URIC ACID;

APOPTOSIS; ARTICLE; CANCER; CELL PROTECTION; CELL STRAIN U937; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERURICEMIA; KIDNEY FAILURE; MONOCYTE; PRECIPITATION; PRIORITY JOURNAL; UREMIA;

APOPTOSIS; CASPASE 3; CASPASE 8; CASPASES; GLUTATHIONE; HUMANS; MONOCYTES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; URATE OXIDASE; URIC ACID;

EID: 20144388701     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570163053175457     Document Type: Article

References (45)

1. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D.: Programmed cell death and the control of cell survival. Philos Trans R Soc Lond B Biol Sci 345(1313), 265-8, (1994).
2. Fisher A., Malissen B.: Natural and engineered disorders of lymphocyte development. Science 280, 237-243, (1998).
3. Cloyd M.W., Chen J.J., Adeqboyega P., Wang L.: How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signalling through its cellular receptors. Curr. Mol. Med. 1(5), 545-50, (2001).
4. Hahne M., Rimoldi D., Schroter M., Romero P., Schreirer M., French L.E., Schneider P., Bornand T., et al.: Melanoma cell expression of Fas (Apo-I/CD95) ligand: implications for tumor immune escape. Science 274, 1363-66, (1996).
5. Liles W.C., Kiener P.A., Ledberter J.A., Aruffo A., Klebanoff S.J.: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184(2), 429-40, (1996).
6. Kohler C., Orrenius S., Zhivotovsky B.: Evaluation of caspase activity in apoptotic cells. J Immunol Methods 265(1-2), 97-110, (2002).
7. Jaber B.I., Cendorologlo M., Balakrishnan V.S., Perianayagam M.C., King A.J., Pereira J.B.: Apoptosis of leukocytes: basic concepts and implications in uremia. Kidney International Vol 50 Suppl. 78, 197-205, (2001).
8. Heidenreich S., Schmidt M., Bachmann J., Harrach B.: Apoptosis of monocytes cultured from long-term hemodialysis patients. Kidney Int 49(3), 792-9, (1996).
9. Ranjan R., Siu J., Varghese E., Bhaskaran M., Reddy K., Kapasi A.A., Wagner J.D., Singhai P.C.: Monocytes apoptosis in dialysis patients is Fas ligand-mediated. Clin. Nephrology Vol. 58 (6), 423-430, (2002).
10. Jaber B.L., Balakrishnan V.S., Cendoroglo M.N., Perianayagam M.C., King A.J., Pereira B.J.: Modulation of neutrophil apoptosis by uremic plasma durino hemodialysis. Blood purification 16(6), 325-35, (1998).
11. Cendoroglo M., Jaber B.L., Balakrishnan V.S., Perianayagam M.C., King A.J., Pereira B.J.: Neutrophil apoptosis and dysfuction in uremia. J. Am. Soc. Nephr. 10(1), 93-100, (1999).
12. D'intini V., Bordoni V., Fortunato A., Galloni E., Carta M., Galli F., Bolgan I., Inguaggiato P., et al.: Longitudinal study of apoptosis in chronic uremic patients. Semin. Dial. 16(6), 467-73, (2003).
13. D'Intini V., Bordoni V., Bolgan I., Bonello M., Brendolan A., Crepaldi C., Gastaldon F., Levin L.W., et al.: Monocyte apoptosis in uremia is normalized with continuos blood purification modalities. Blood Purif. 22(1), 9-12, (2004).
14. Rose B.D., Pathophysiology of Renal Disease; 2d ed.; McGraw-Hill: New York, 418-25, (1987).
15. Kjellstrand C.M., Cambell D.C., von Hartitzsch B., Buselmeier T.J.: Hyperuricemic acute renal failure. Arch Intern Med. 133(3), 349-59, (1974).
16. Mandel N.: Crystal-membrane interaction in kidney stone disease. J Am Soc Nephrol. 5 (5 Suppl 1), S37-45, (1994).
17. Johnson R.J., Kivlighn S.D., Kim Y.G., Suga S., Fogo A.B.: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 33(2), 225-34, (1999).
18. Leyva F., Anker S.D., Godsland I.F., Teixeira M., Hellewell P.G., Kox W.J., Poole-Wilson P.A., Coats A.J.: Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 19(12), 1814-22, (1998).
19. Umekawa T., Chegini N., Khan S.R.: Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 18(4), 664-9, (2003).
20. Meng Z.H., Hudson A.P., Schumacher H.R. Jr., Baker J.F., Baker D.G.: Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumor necrosis factor-alpha expression in a mononuclear cell line. J Rheumatol. 24(12), 2385-8, (1997).
21. Matsukawa A., Yoshimura T., Maeda T., Takahashi T., Ohkawara S., Yoshinaga M.: Analysis of the cylokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest. 78(5), 559-69, (1998).
22. Louyot P., Montet Y., Roland J., Pourel J.: Urate oxidase in the treatment of gout and hyperuricemia. Rev Rhum Mal Osteoartic 37(12), 795-808, (1970).
23. Cairo M.S.: Prevention and treatment of hyperuricemia in haematological malignancies. Clin Lymphoma 3 (suppl 1), S26-S31, (2002).
24. Wolf G., Hegewisch-Becker S., Hossfeld D.K., Stahl RA: Hyperuricemia and renal insufficiency associated with malignant disease: Urate oxidase as an efficient therapy?. Am. J. Kidney Dis. 34(5): E20, (1999).
25. Dini L., Coppola S., Ruzittu M.T., Ghibelli L.: Multiple pathways for apoptotic nuclear fragmentation. Exp Cell Res 223, 340-347, (1996).
26. Talanian R.V., Quinlan C., Trautz S., Hackett M.C., Mankovich J.A., Banach D., Ghayur T., Brady K.D., et al.: Substrate specificities of caspase family proteases. J. Biol. Chem. 272(15), 9677-82, (1997).
27. Anderson M.E.: Enzimatic and chemical methods for the determination of glutathione. Glutathione: chemical, biochemical and medical aspects, Dolphin D., Poulson R. and Avramovic O. Eds., John Wiley and Sons: Vol. A, pp. 339-365, (1989).
28. Ghibelli L., Fanelli G., Rotilio E., Lafavia S., Coppola S., Colussi C., Civotareale P., Ciriolo R.: Resque of cells from apoptosis by inhibition of active GSH extrusion. FASEB J. 12, 479-86, (1998).
29. Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., Clark W., Cohen G., et al.: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63(5), 1934-43, (2003).
30. Vanholder R., Argiles A., Baurmeister U, Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., et al.: Uremic toxicity: present state of the art. Int J Artif Organs 24(10), 695-725, (2001).
31. Iseki K., Oshiro S., Tozawa M., Iseki C., Ikemiya Y., Takishita S.: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 24(6), 691-7, (2001).
32. Lhotta K., Gruber J., Sgonc R., Fend F., Konig P.: Apoptosis of tubular epithelial cells in familial juvenile gouty nephropathy Nephron. 79(3), 340-4, (1998).
33. Tudan C., Fong D., Duronio V., Burt H.M., Jackson J.K.: The inhibition of spontaneous and tumor necrosis factor-alpha induced neutrophil apoptosis by crystals of calcium pyrophosphate dihydrate and monosodium urate monohydrate. J Rheumatol 27(10), 2463-72, (2000).
34. Akahoshi T., Nagaoka T., Namai R., Sekiyama N., Kondo H.: Prevention of neutrophil apoptosis by monosodium urate crystals. Rheumatol Int. 16(6), 231-5, (1997).
35. Kou C.C., Shis M.C., Kou Y.H., Chiang W.: Antagonism of free-radical-induced damage of adlay seed and its proliferative effect in human histolytic lymphoma U937 monocytic cells. J Agric. Food Chem. 49(3), 1564-70, (2001).
36. Leach M., Parsons K.M., Reilly J.T., Winfield D.A: Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol. 20(3), 169-72, (1998).
37. Cairo M.S.: Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 3 Suppl 1, S26-31, (2002).
38. Grutter M.G.: Caspases: key players in programmed cell death. Curr. Opin. Struct Biol 10(6), 649-55, (2000).
39. Chinnaiyan A.M., Tepper C.G., Seldin M.F., O'Rourke K., Kischkel F.C., Hellbardt S., Krammer P.H., Peter M.E., et al.: FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271(9), 4961-5, (1996).
40. Green D.R, Reed C.: Mitochondria and apoptosis. Science 281, 1309-12, (1998).
41. Ghibelli L., Coppola S., Fanelli C., Rotilio P., Civitarelli P., Scovassi A.I., Circolo M.R.: Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis. FASEB J. 13, 2031-36, (1999).
42. Musallam L., Ethier C., Haddad PS., Denizeau F., Bilodeu M.: Resistance to Fas-induced apoptosis in hepatocytes: role of GSH depletion by cell isolation and culture. Am J Physiol Gastrointest Liver Physiol. 283(3), G709-18, (2002).
43. Coppola S., Ghibelli L.: GSH extrusion and mitochondrial pathway of apoptotic signaling. Biochem. Soc. Trans. 28 (2), 56-61, (2000).
44. Li H., Zhu H., Xu C.J., Yaun J.: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501, (1996).
45. Luo X., Budihardjo I., Zou C., Slaughter C., Wang X.: Bid, a bcl2 interacting protein, mediates cytochrome c realese from mitochoncdria in response to activation of cell surface death receptors. Cell 94, 481-90, (1998).